- Home
- FOF vs FENC Comparison
FOF vs FENC Comparison
Compare FOF & FENC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
SELL
HOLD
Current Price
$10.93
Company Overview
Basic Information| Metric | FOF | FENC |
|---|---|---|
| Founded | 2006 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 375.8M | 366.8M |
| IPO Year | N/A | 2010 |
Fundamental Metrics
Financial Performance| Metric | FOF | FENC |
|---|---|---|
| Price | $12.40 | $10.93 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $17.67 |
| AVG Volume (30 Days) | 61.1K | ★ 104.8K |
| Earning Date | 01-01-0001 | 11-12-2026 |
| Dividend Yield | ★ 9.07% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.06 |
| Revenue | N/A | ★ $44,642,000.00 |
| Revenue This Year | N/A | $62.55 |
| Revenue Next Year | N/A | $42.10 |
| P/E Ratio | ★ N/A | $180.50 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $11.99 | $5.65 |
| 52 Week High | $15.04 | $13.25 |
Technical Indicators
Market Signals| Indicator | FOF | FENC |
|---|---|---|
| Relative Strength Index (RSI) | 51.27 | 55.09 |
| Support Level | $12.12 | $9.87 |
| Resistance Level | $12.60 | $11.29 |
| Average True Range (ATR) | 0.17 | 0.50 |
| MACD | 0.03 | 0.09 |
| Stochastic Oscillator | 67.77 | 71.01 |
Price Performance
Historical Comparison FOF
FENC
About FOF Cohen & Steers Closed-End Opportunity Fund Inc.
Cohen & Steers Closed-end Opp Fd Inc is a diversified, closed-ended management investment company. The Fund's investment objective is to achieve total return, consisting of high current income and potential capital appreciation.
About FENC Fennec Pharmaceuticals Inc.
Fennec Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. Its product candidate is PEDMARK which is sodium thiosulfate in a novel formulation for the prevention of cisplatin-induced hearing loss, or ototoxicity in children. The company principally operates in the United States.